clinical trial · NCT07358377
A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative Cancer
Atridia Pty Ltd.·phase1·recruiting·n = 15
Breast CancerHRS-6209 Capsules and fulvestrant injection
brief summary
To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects with HR-Positive/HER2-Negative solid tumor.
started
May 15, 2026
primary completion
Apr 10, 2027
completion
Nov 10, 2027
last updated
Aug 11, 2026
official title
An Open-Label, Multi-Center Phase II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HRS-6209 in Combination With Fulvestrant or Letrozole in Patients With Solid Tumor
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol